PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
-9.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
48.96%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
53.59%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
51.99%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.21%
Share change of 10.21% while TRVN is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
6.42%
Diluted share change of 6.42% while TRVN is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-60.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-15675.30%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-5709.37%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-6838.40%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
530.49%
Equity/share CAGR of 530.49% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
431.75%
Equity/share CAGR of 431.75% while TRVN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-71.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while TRVN stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
52.82%
R&D growth drastically higher vs. TRVN's 89.71%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-14.04%
We cut SG&A while TRVN invests at 38.98%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.